These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 37768030)
1. Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004). Kim NK; Kim Y; Kim HS; Park SJ; Hwang DW; Lee SJ; Yoo JG; Chang SJ; Son JH; Kong TW; Kim J; Shim SH; Lee AJ; Suh DH; Lee YY Cancer Med; 2023 Oct; 12(19):19449-19459. PubMed ID: 37768030 [TBL] [Abstract][Full Text] [Related]
2. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients]. Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575 [No Abstract] [Full Text] [Related]
3. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer. Guo Y; Chen X; Tang X; Pan S; Zhu T; Zhang Y Curr Cancer Drug Targets; 2024; 24(7):733-748. PubMed ID: 38173064 [TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662 [TBL] [Abstract][Full Text] [Related]
7. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy. Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005 [TBL] [Abstract][Full Text] [Related]
8. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830 [TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. Lee EK; Matulonis UA Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431 [TBL] [Abstract][Full Text] [Related]
11. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB PLoS One; 2023; 18(11):e0294647. PubMed ID: 37976295 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gonzalez R; Havrilesky LJ; Myers ER; Secord AA; Dottino JA; Berchuck A; Moss HA Gynecol Oncol; 2020 Nov; 159(2):483-490. PubMed ID: 32863036 [TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. Gong H; Nie D; Huang Y; Li Z Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083 [TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL; Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262 [TBL] [Abstract][Full Text] [Related]
15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for Zhang M; Yu X; Wang J; Li Y; Cao L J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738 [TBL] [Abstract][Full Text] [Related]
17. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK; J Clin Oncol; 2024 Apr; 42(11):1301-1310. PubMed ID: 38215359 [TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis. Peters ITA; Marchetti C; De Palma A; Giannarelli D; Carcagnì A; Scambia G; Fagotti A Eur J Cancer; 2023 Jul; 187():77-86. PubMed ID: 37130463 [TBL] [Abstract][Full Text] [Related]
19. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773 [TBL] [Abstract][Full Text] [Related]
20. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]